Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with rheumatoid arthritis: Results from RA-BEYOND

CONCLUSION: Oral baricitinib maintained lower levels of radiographic progression than initial csDMARD or placebo through 5 years in patients with active RA.PMID:34526397 | DOI:10.3899/jrheum.210346

Source: Journal of Rheumatology - September 16, 2021 Category: Rheumatology Authors: D ésirée van der Heijde Cynthia E Kartman Li Xie Scott Beattie Douglas Schlichting Daojun Mo Patrick Durez Yoshiya Tanaka Roy Fleischmann Source Type: research